Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
Palvella Therapeutics announced the issuance of U.S. Patent No. 12,636,273, exclusively licensed from Yale University, which strengthens the IP position for its QTORIN pitavastatin program. The patent covers topical administration of HMG-CoA reductase inhibitors for the treatment of porokeratosis, including disseminated superficial actinic porokeratosis (DSAP), providing protection into 2043.
Key figures
- Drug Name
- QTORIN pitavastatin
- Phase Of Trial
- Phase 2
- Patent expiry
- 2043
- Us patent number
- 12,636,273
- Dsap patient population us
- 50,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.